Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Age-specific mortality rates
3. UK audit - cases
4. Role of HPV testing in cervical screening (1)
5. Role of HPV testing in cervical screening (2)
6. "HPV testing is at least as good"
7. Baseline results of HPV testing
8. Aims
9. Studies included
10. HPV positivity by age - common shape
11. Cytology sensitivity - CIN2+ (all ages)
12. HPV sensitivity - CIN2+ (all ages)
13. Cytology positivity - normal (all ages)
14. HPV positivity - normal (all ages)
15. HPV positivity - normal (ages = or more than 35)
16. Summary
17. Subsequent studies
18. Double-testing studies after overview
19. Randomised trials - first round
20. Long-term follow-up of HPV testing
21. Cumulative incidence of CIN2+
22. Cumulative incidence rate for CIN3+
23. Conclusions
24. Proposed new screening algorithm
25. HPV typing
26. mRNA testing
27. Other potential adjunctive tests
28. Potential future screening algorithm

Topics Covered

• Cases of cervical cancer in the UK
• Potential role of HPV testing in cervical screening
• Baseline results of HPV testing in European and North American screening studies
• HPV positivity by age
• Cytology sensitivity and positivity
• HPV sensitivity and positivity
• Double-testing studies
• Randomized trials
• Long-term follow-up of HPV testing: results from the Hammersmith study
• Proposed new screening algorithm
• HPV typing
• mRNA testing
• Other potential adjunctive tests
• Potential future screening algorithm

Links

Series:

• Viruses and Viral Diseases

Categories:

• Clinical Practice
• Methods
• Microbiology
• Reproduction & Development

Therapeutic Areas:

• Gynaecology & Obstetrics
• Infectious Diseases

Talk Citation

Cuzick, J. (2010, July 15). Can HPV testing be the sole primary cervical screening modality? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/DKSA5204.
Export Citation (RIS)

Publication History

• Published on July 15, 2010
• Archived on December 31, 2017

Financial Disclosures

• Prof. Jack Cuzick has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.